Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2004

View Archived Issues

Medarex to receive milestone payment from Amgen for antibody development

Gilead Sciences and Achillion collaborate on HCV compounds

Dyax grants use of antibody phage display libraries to Tanox

Amendment to terms of Vitex/Panacos merger

Progression of Lipid Sciences' Viral Immunotherapy program

Cardiome selects oral controlled-release formulation of RSD-1235

BioMarin plans phase III trial of Phenoptin for 2005

Medivir and Tibotec enter HCV license and research collaboration agreement

Avidia and Boehringer Ingelheim in development and manufacturing agreement

Bleeding associated with serotonin reuptake inhibition

HER2/ERBB3 pathway implicated in hormone refractory prostate cancer

A new prednisolone formulation shows promise in the treatment of UC

Clinical data on the efficacy of fenretinide in recurrent malignant gliomas

Cognitive benefits found with donepezil in MS patients with verbal memory impairment

Groundbreaking study to explore benefits of long-term pimecrolimus treatment

Good safety profile reported for C31G vaginal gel in healthy volunteers

New compounds for the treatment of psychiatric and mood disorders

Merck claims a series of CGRP receptor antagonists

GABA-A receptor modulators described by NeuroSearch

A series of protein tyrosine phosphatase inhibitors described in a patent

Dual acting compounds for the treatment of psychiatric disorders

Novel MAP kinase/TNF inhibitors in early development at Pfizer

Novartis researchers describe beta2-adrenergic agonists

Antibacterial oxazolidinones claimed by Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...